CAR T Cell Therapy News
FDA approves tisagenlecleucel (commercial name Kymriah) CAR T cell therapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma.
Cheryl Wiers knew her cancer diagnosis happened for a reason, and for her, that reason could be her participation in a clinical trial using what is arguably the most promising cancer treatment — CAR T cell therapy.
CAR T Cells Save Chuck Fata's Life
City of Hope physicians have successfully treated blood cancers with chimeric antigen receptor (CAR) T cell therapy, and they are working to expand that therapy to patients with prostate cancer and other solid tumors.
City of Hope today announced that it is a certified treatment center to administer tisagenlecleucel (commercial name Kymriah) chimeric antigen receptor (CAR) T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration (FDA) – to patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
City of Hope recently announced that it is a certified treatment center to administer tisagenlecleucel CAR T cell therapy – the first CAR T cell therapy approved by the U.S. Food and Drug Administration – to patients.
City of Hope, a world-renowned independent research and treatment center for cancer and diabetes, will highlight a variety of basic research and population studies at the annual meeting of the American Association for Cancer Research (AACR) in Chicago’s McCormick Place April 14 to 18.
Often unrecognized are the countless folks who work in the spaces between the lab and the clinic — people responsible for doing everything from manufacturing CAR T cells to gaining federal approval for new trials.
In memory of Ben and Beverly Horowitz, longtime chief executive officer and first lady of City of Hope, their family has donated $1 million to City of Hope to help advance groundbreaking CAR-T cell immunotherapy research to combat cancer.
CEA remains one of the most widely used clinical markers of cancer. As the diverse roles of CEA and CEACAMs, have grown clearer, researchers at City of Hope are working on a new wave of clinical tools and therapies.
As an affiliate of City of Hope, TGen will use its genomics expertise to chart a path to greater precision in CAR T therapies for cancer patients.
Christine Brown, Ph.D., co-leads the T Cell Therapeutics Research Laboratory, along with Stephen J. Forman, M.D., which to date has treated more than 100 patients in seven clinical trials, with aggressive goals of opening four new clinical studies within the year.
Larry Kwak, M.D., Ph.D., received a grant to support his work with mantle cell lymphoma from the Leukemia & Lymphoma Society, the world’s largest voluntary health organization dedicated to fighting blood cancer.
Xiuli Wang, Ph.D., is at the forefront of one of the most exciting breakthroughs in cancer treatment, chimeric antigen receptor (CAR) T cell therapy.